Pharmacodynamic study of FS-0311: A novel highly potent, selective acetylcholinesterase inhibitor

Cellular and Molecular Neurobiology

Volumn 28, Issue 2, 2008, Pages 245-261

  Wang, Zhi Fei ^a   Yan, Jin ^a   Fu, Yan ^a   Tang, Xi Can ^a   Feng, Song ^a   He, Xu Chang ^a   Bai, Dong Lu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Amyloid; Alzheimer's disease; Antioxidant enzymes; Cholinesterase inhibitor; Huperzine B derivative; Oxygen glucose deprivation; Scopolamine; Staurosporine; Transient brain ischemia and reperfusion; Water maze

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CHOLINESTERASE INHIBITOR; DONEPEZIL; FS 0311; GLUTATHIONE PEROXIDASE; HUPERZINE A; HUPERZINE B; NOOTROPIC AGENT; SCOPOLAMINE; STAUROSPORINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; CELL PROTECTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; MAZE TEST; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ALZHEIMER DISEASE; ANIMALS; BRAIN ISCHEMIA; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DRUGS, CHINESE HERBAL; FEMALE; MALE; MAZE LEARNING; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY;

MUS;

EID: 39149143624     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10571-007-9199-0     Document Type: Article

References (34)

1. Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827
2. Bejar C, Wang RH, Weinstock M (1999) Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 383:231-240
3. Bonner LT, Peskind ER (2002) Pharmacologic treatments of dementia. Med Clin North Am 86:657-674
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
5. Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M (1996) An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302:13-20
6. Castro A, Martinez A (2001) Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev Med Chem 1:267-272
7. Cheung RT (2003) The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 34:153-160
8. Coyle JT, Price DL, DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219:1184-1190
9. de Bruin N, Pouzet B (2006) Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 85:253-260
10. Feng S, Wang Z, He X, Zheng S, Xia Y, Jiang H, Tang X, Bai D (2005) Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem 48:655-657
11. Gilgun-Sherki Y, Melamed E, Offen D (2003) Antioxidant treatment in Alzheimer's disease: current state. J Mol Neurosci 21:1-11
12. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16:881-891
13. Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR (2006) In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann Neurol 59:13-20
14. Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, Shalaby IA, Ramirez A, Nason D, White WF (2004) Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 486:9-17
15. Liu J, Zhang HY, Wang LM, Tang XC (1999) Inhibitory effects of huperzine B on cholinesterase activity in mice. Zhongguo Yao Li Xue Bao 20:141-145
16. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147
17. McCord JM, Fridovich I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244:6049-6055
18. Mills GC (1959) The purification and properties of glutathione peroxidase of erythrocytes. J Biol Chem 234:502-506
19. Munoz-Ruiz P, Rubio L, Garcia-Palomero E, Dorronsoro I, del Monte-Millan M, Valenzuela R, Usan P, de Austria C, Bartolini M, Andrisano V, Bidon-Chanal A, Orozco M, Luque FJ, Medina M, Martinez A (2005) Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem 48:7223-7233
20. Onyango IG, Khan SM (2006) Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Curr Alzheimer Res 3:339-349
21. Pacheco G, Palacios-Esquivel R, Moss DE (1995) Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 274:767-770
22. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S (1996) Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem 271:23646-23649
23. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871-877
24. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S (2003) Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 24:777-787
25. Rosini M, Andrisano V, Bartolini M, Bolognesi ML, Hrelia P, Minarini A, Tarozzi A, Melchiorre C (2005) Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 48:360-363
26. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S (1996) Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 103:1211-1220
27. Wang T, Tang XC (1998) Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 349:137-142
28. Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC (2006) Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 83:603-611
29. Wang ZF, Zhou J, Tang XC (2002) Huperzine B protects rat pheochromocytoma cells against oxygen-glucose deprivation-induced injury. Acta Pharmacol Sin 23:1193-1198
30. Weinstock M, Goren T, Youdim MBH (2000) Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Develop Res 50:216-222
31. Xu H, Tang XC (1987) Cholinesterase inhibition by huperzine B. Zhongguo Yao Li Xue Bao 8:18-22
32. Yagi K (1976) A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 15:212-216
33. Yan XF, Lu WH, Lou WJ, Tang XC (1987) Effects of huperzine A and B on skeletal muscle and the electroencephalogram. Zhongguo Yao Li Xue Bao 8:117-123
34. Yuan J, Yankner BA (2000) Apoptosis in the nervous system. Nature 407:802-809